David Ellam
CFO
Finance
Silence Therapeutics
Germany
Biography
David was appointed Chief Financial Officer and Company Secretary of Silence in July 2016. David holds a B.A. in English & Philosophy from Birmingham University, and is a qualified chartered accountant. Prior to joining Silence, David’s relevant Biotech experience includes several senior finance roles within both UK and US publicly owned life science companies, most recently as Senior EUMEA Finance Director for BioMarin Pharmaceuticals Inc. from 2010 to 2016. Prior to that he was CFO at Plethora Solutions plc (2008-2009), and Group Financial Controller at Ark Therapeutics from 2001 to 2008, during which time Ark undertook an IPO on the London Stock Exchange.
Research Interest
Business and Management
